自研+BD 双轮驱动，创新转型已见成效。翰森制药深耕医药行业30 年，经营情况稳中向好，2023 年营收突破100 亿元，同比增长7.70%，净利润突破30亿元，同比增长26.85%。公司坚持“自主研发”和“BD 合作”双轮驱动，以“高强度研发投入加速临床进展、高价值创新药扩充产品管线、高差异早期项目引领科研布局、高投入基础研究激活源头创新”的战略，持续加强成熟创新产品与高差异化早期项目引进，公司...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.